Hi,
moomoo ID:NaN
Log Out
English
Back
Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
02190 ZYLOXTB-B
11.420
+0.940+8.97%
YOY
Do not show
Hide blank lines
(Q6)2022/06/30(FY)2021/12/31(Q6)2021/06/30(FY)2020/12/31
Turnover
113.67% 152.74M 543.89% 177.91M 3,291.08% 71.48M 461.95% 27.63M
Operating income
113.67% 152.74M 543.89% 177.91M 3,291.08% 71.48M 461.95% 27.63M
Cost of sales
-92.49% -37.27M -305.77% -46.03M -1,166.19% -19.36M -204.54% -11.34M
Operating expenses
-92.49% -37.27M -305.77% -46.03M -1,166.19% -19.36M -204.54% -11.34M
Gross profit
121.54% 115.48M 709.73% 131.88M 8,902.42% 52.12M 1,266.36% 16.29M
Selling expenses
-107.13% -53.33M -365.79% -95.27M -427.82% -25.75M -202.60% -20.45M
Administrative expenses
9.01% -49.28M -224.60% -100.6M -656.80% -54.16M -82.71% -30.99M
Research and development expenses
-92.00% -94.04M -133.26% -168.1M -78.40% -48.98M -35.90% -72.07M
Impairment and provision
-- 10K -- -21K -- -- -- --
-Other impairment is provision
-- 10K -- -21K -- -- -- --
Special items of operating profit
307.89% 19.79M 178.03% 19.63M 8.35% 4.85M -28.36% 7.06M
Operating profit
14.65% -61.38M -112.13% -212.48M -108.85% -71.91M -52.45% -100.16M
Financing income
1,485.33% 36.3M 3,537.22% 13.09M 2,874.03% 2.29M 304.49% 360K
Financing cost
-364.52% -432K 53.90% -307K 79.05% -93K 35.65% -666K
Earning before tax
63.42% -25.5M -98.76% -199.69M -100.34% -69.72M -50.75% -100.47M
After-tax profit from continuing operations
63.42% -25.5M -98.76% -199.69M -100.34% -69.72M -50.75% -100.47M
Earning after tax
63.42% -25.5M -98.76% -199.69M -100.34% -69.72M -50.75% -100.47M
Profit attributable to shareholders
63.42% -25.5M -98.76% -199.69M -100.34% -69.72M -50.75% -100.47M
Basic earnings per share
70.37% -0.08 -30.77% -0.68 -42.11% -0.27 -36.84% -0.52
Diluted earnings per share
70.37% -0.08 -30.77% -0.68 -42.11% -0.27 -36.84% -0.52
Currency Unit
CNYCNYCNYCNY
Accounting Standards
IASIASIASIAS
Audit Opinions
--Unqualified Opinion--Unqualified Opinion
Auditor
--PricewaterhouseCoopers--PricewaterhouseCoopers

Q6, Q9, and FY are cumulative quarterly reports: Q6 is the interim report; Q9 is third quarter report; FY is the annual report.

The MOM data from the Quarterly report,MOM=(current period - last period)/last period *100%

Company Overview More
Guichuang Tongqiao Medical Technology Co., Ltd. is one of the leaders in China's peripheral and neurovascular implants in the medical equipment market. As a comprehensive and comprehensive medical device company, we have strong R & D and manufacturing capabilities, professional technology platform and mature commercial capabilities. Under the leadership of an excellent management team, we continue to provide humane medical services and advanced overall solutions to doctors and patients in China and overseas. We are a comprehensive solution provider that provides the most comprehensive product solutions for peripheral and neurovascular interventional medical equipment. Since its establishment in 2012, we have systematically and systematically developed 45 high-quality products, fully covering the rapidly growing neurological and peripheral vascular disease market. In China, we are the only domestic medical device company approved by CE to sell peripheral and neurovascular intervention products in Europe, including peripheral bare metal stents, drug-eluting stents (DES), PTA balloons, drug balloons (DCB) and high pressure PTA balloons, as well as thrombectomy stents.
CEO: Jonathon Zhong Zhao
Market: Hong Kong motherboard
Listing Date: 07/05/2021
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...

Watchlist